Please turn JavaScript on

Stevenage Bioscience Catalyst

Want to know the latest news and articles posted on Stevenage Bioscience Catalyst?

Then subscribe to their feed now! You can receive their updates by email, via mobile or on your personal news page on this website.

See what they recently published below.

Website title: Stevenage Bioscience Catalyst: Empowering Innovation

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  0.12 / day

Message History

Obituary: Dr Sally Ann Forsyth OBE DSc Dr Sally Ann Forsyth OBE DSc was one of the UK life sciences sector’s most respected and influential leaders, dedicating her career to supporting science, innovation and collaboration across the scientific community. Throughout more than three decades in the sector, she played a significant role in helping ambitious...

Read full story
Stevenage Bioscience Catalyst is deeply saddened to share the news that our CEO, Dr Sally Ann Forsyth OBE, passed away at home on Saturday 2 May after a long battle with illness. Dr Sally Ann Forsyth OBE played a significant role in shaping SBC into the thriving life sciences community it is today. Her vision, determination and longstanding commitment to advancing health innovat...

Read full story
We were honoured to welcome Her Royal Highness The Duchess of Edinburgh to Stevenage Bioscience Catalyst. Her Royal Highness toured the campus and met a selection of early-stage companies developing new treatments across cancer, women’s health and RNA-based medicines, and heard how science on campus is being translated into real impact for patients, alongside support for local S...

Read full story
Santo Therapeutics Announces Dual FDA Designations for ST002 in NF2 Santo Therapeutics today announced that its lead program, ST002, has received both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration for the treatment of NF2-related schwannomatosis (NF2-SWN).

The dual FDA designations, granted within a shor...


Read full story